Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder
Portfolio Pulse from Benzinga Newsdesk
Neuronetics, Inc. (NASDAQ:STIM) announced that additional payors, including BlueCross BlueShield of North Carolina and Louisiana Medicaid, have updated their TMS coverage policies. This expansion reduces access barriers for patients with major depressive disorder, allowing earlier treatment with NeuroStar TMS Therapy.
September 19, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neuronetics has announced expanded TMS coverage by major payors, including BCBS of North Carolina and Louisiana Medicaid, enhancing access for patients with major depressive disorder. This could lead to increased adoption of NeuroStar TMS Therapy.
The expansion of TMS coverage by major payors like BCBS of North Carolina and Louisiana Medicaid is significant for Neuronetics as it directly increases the potential patient base for their NeuroStar TMS Therapy. This could lead to higher sales and revenue, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100